Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)‐AML206 study
暂无分享,去创建一个
T. Naoe | C. Nakaseko | Y. Miyazaki | H. Kiyoi | S. Miyawaki | A. Takeshita | S. Ohtake | K. Ohnishi | Yukio Kobayashi | T. Sakura | C. Ohwada | N. Dobashi | N. Usui | K. Shigeno | H. Fujita | Y. Yahagi | Y. Kobayashi
[1] R. Vij,et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. , 2011, Leukemia research.
[2] T. Naoe,et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.
[3] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Xiuqiang Wang,et al. Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). , 2010 .
[5] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[6] T. Naoe,et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study , 2009, International journal of hematology.
[7] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[8] P. Chevallier,et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Voso,et al. Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia , 2007 .
[10] H. Kantarjian,et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy , 2005, British journal of haematology.
[11] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[12] M. Baccarani,et al. Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas , 2004, Leukemia & lymphoma.
[13] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Rohatiner,et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .
[15] G. Garcia-Manero,et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. , 2003, Leukemia research.
[16] I. Bernstein,et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.
[17] E. Estey,et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia , 2002, Cancer Chemotherapy and Pharmacology.
[18] R. Larson. Current use and future development of gemtuzumab ozogamicin. , 2001, Seminars in hematology.
[19] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] I. Bernstein,et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.
[22] E. Estey. Treatment of relapsed and refractory acute myelogenous leukemia , 2000, Leukemia.
[23] Z. Darżynkiewicz,et al. Phase II Evaluation of a High-Dose Mitoxantrone Based Induction Regimen in Untreated Adults with Acute Myeloid Leukemia , 2000, Leukemia & lymphoma.
[24] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[25] D. Niederwieser,et al. Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). , 1994, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[26] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.
[27] I. Bernstein,et al. Expression of normal myeloid-associated antigens by acute leukemia cells. , 1986, Blood.